NCT00324220 - A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Myelodysplastic SyndromeAcute Myelogenous Leukemia

Interventions

DRUG

MGCD0103

MGCD0103 Oral administration 3 times per week.

Trial Locations (8)

Memorial Sloan-Kettering Cancer Center, New York

The Western Pennsylvania Hospital, Pittsburgh

University of Pennsylvania, Philadelphia

Thomas Jefferson University Hospital, Philadelphia

Thomas Jefferson University, Philadelphia

St. Francis Hospital & Health Center, Beech Grove

University of Texas, MD Anderson Cancer Center, Houston

University of Southern California, Los Angeles